Xconomy: Acceleron, Bucking Conventional Wisdom, Pushes Ahead Drug For Bone Loss, Anemia
Summary
Acceleron, Bucking Conventional Wisdom, Pushes Ahead Drug For Bone Loss, Anemia (Page 2 of 2) its lab and office space on Cambridge’s Sidney Street by almost 20,000 square feet.The announcement at that time only disclosed promising results for the experimental drug’s ability to spur formation of bone, and didn’t say anything about also boosting red blood cell production.The two companies have worked to build on the early momentum with a pair of more rigorous mid-stage clinical trials of patients with multiple myeloma (a malignancy of the bone marrow), and breast cancer.Acceleron isn’t saying how much cash it has left, but Knopf says he’s looking to partners to help foot the bills, particularly for its two other drugs in development—ACE-031 for increasing muscle mass, and ACE-041 to cut off blood flow to tumors.Knopf talked it up a fair bit during our conversation Wednesday, and just yesterday, Acceleron presented data at a medical meeting in Switzerland that shows the drug increased lean body mass and muscle volume in a small clinical trial.